Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 10/28/26 | Eli Lilly (LLY) | retatrutide for Diabetes Mellitus, Type II | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/26/26 | Leads Biolabs | LBL-024 for Neuroendocrine Tumors (NET) | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/26/26 | Coherus Oncology (CHRS) | Loqtorzi for Non-Small Cell Lung Cancer (NSCLC) | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/26/26 | Merck & Co (MRK) | Keytruda for Uterine (Endometrial) Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/26/26 | Merck & Co (MRK) | Jiatailai for Uterine (Endometrial) Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 07/31/2025 | Subscribers Only | Subscribers Only | Regulatory - sNDA/sBLA Filing |
| 07/31/2025 | Subscribers Only | Subscribers Only | Regulatory - IND/CTA Filing |
| 10/28/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 10/31/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 11/11/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |